William Blair analyst Andrew Brackmann has reiterated their bullish stance on GH stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Guardant Health’s strong growth potential and strategic advancements. The company’s investor day showcased its robust platform in precision oncology diagnostics, emphasizing its capacity for substantial and profitable growth. Guardant Health’s flagship G360 test has paved the way for expansion into new testing categories and patient populations, enhancing its data collection for internal research and collaborations with biopharma partners.
Furthermore, specific updates from the event included the anticipated launch of Shield for multi-cancer detection and Reveal for therapy monitoring. Financially, Guardant Health has increased its 2028 revenue target to $2.2 billion, indicating a significant revenue growth rate. The company also aims to achieve free-cash-flow breakeven by the fourth quarter of 2027, a year earlier than previously expected. These strategic and financial developments underpin Brackmann’s confidence in the company’s future performance.
In another report released today, Barclays also maintained a Buy rating on the stock with a $60.00 price target.